世卫组织回应中国疫苗事件 赞扬药监部门

世界卫生组织（世卫组织）完全支持中国国家药品监督管理局（中国国家药监局）扣留问题批次狂犬病疫苗、使其不能进入市场的行动。

国家药监局在对位于中国吉林省的疫苗生产厂家——长春长生生物科技股份有限公司的生产场地进行飞行检查时，查出该公司在涉事批次狂犬病疫苗生产过程中存在记录造假的问题。政府已经扣留了所有涉事疫苗，避免给患者使用问题疫苗，并停止了该公司的疫苗生产。世卫组织正在等待进一步的调查结果，并随时准备向中国国家卫生主管部门提供支持。

有效的药品生产质量管理和监管是为了预防问题和确保疫苗质量。但一旦发现问题，监管部门必须要采取行动。世卫组织赞扬中国国家药监局采取迅速而透明的行动，停止其生产并对事件展开调查。

世卫组织在2010年和2014年对中国国家药监部门进行过两次评估。结果显示国家药监部门达到了世卫组织充分行使职能的监管机构的标准，并明确承诺会继续改进。世卫组织欢迎中国国家药监局继续与世卫组织的加强国家监管部门的合作，这一合作已经开展了近20年。本次事件无疑令人遗憾，但此次事件由飞行检查发现，也说明了监管机构的体系监管和现场检查能有效保护人民健康。

世卫组织重申质量可靠的疫苗对于预防疾病至关重要，并鼓励各国继续采用这一具有成本效益性的公共卫生干预措施。中国的扩大免疫规划颇具成效，让中国实现了无脊髓灰质炎状态，并大幅减少了中国儿童中的麻疹、腮腺炎、风疹、甲肝和乙肝等疫苗可预防疾病。为此，世卫组织还对中国的疫苗生产商提供支持，使其达到国际标准和世卫组织预认证的要求。

WHO STATEMENT ON RABIES VACCINE INCIDENT IN CHINA

The World Health Organization (WHO) fully supports China’s National Drug Administration’s (NDA’s) actions to withhold the problematic batches of rabies vaccine and ensure they are not placed on the market.During an unannounced inspection at the manufacturing site of Changchun Changsheng Life Sciences Ltd.， a vaccine manufacturer in China’s northeastern Jilin province， the NDA discovered problems of data integrity in the production of the batches of rabies vaccine. Authorities have withheld all vaccines involved， to prevent their reaching patients， and suspended production at the company. WHO awaits the results of further investigations and stands ready to provide support to national health authorities.

“Regulatory oversight of vaccines is critically important. It is the government's primary method of ensuring that the vaccines produced and used in China are safe， of good quality and effective，” said Gauden Galea， WHO Representative for China. “This incident shows that when regulatory oversight works well， potential risks can be averted.”

Good manufacturing and regulatory practices are designed to prevent problems in the process of ensuring quality vaccines. But when problems are found， the regulator must take action. WHO commends the quick and transparent actions taken by China NDA to suspend production at the company and investigate these incidents.

WHO assessed the national regulatory authorities in 2010 and 2014， and found that they met WHO criteria as a functional regulator for vaccines with a clear commitment to continual improvement. WHO welcomes the fact that China's NDA continues to work with WHO's Regulatory Systems Strengthening program， as it has been doing for nearly 20 years. While the current incident is clearly regrettable， the detection of this event by an unannounced inspection shows that the regulatory authority’s system of checks and balances to protect population health is working.

WHO reiterates that quality-assured vaccines are critical for disease prevention and urges countries to continue using this cost-effective public health intervention. The Expanded Program on Immunization in China has brought results. It has made China free from polio and significantly reduced vaccine-preventable diseases such as measles， mumps， rubella， and hepatitis A and B among children. To that end， WHO is also supporting vaccine manufacturers in China to ensure that they comply with international standards and meet WHO Prequalification expectations.